Cost-per-responder analysis for eltrombopag and rituximab in the treatment of primary immune thrombocytopenia in Spain

Autor: González-Porras,José Ramón, Parrondo García,Francisco Javier, Anguita,Eduardo

Publikováno v: Farmacia Hospitalaria, Vol 44, Iss 6, Pp 279-287 (2020)
Farmacia Hospitalaria v.44 n.6 2020
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname

Splenectomy, thrombopoietin receptor agonists and rituximab are the second-line treatments for steroid-resistant adult primary immune thrombocytopenia. The last two are becoming the most widely used treatments to avoid splenectomy adverse effects and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b085abc87b6850c37fc32c095c4192db
https://pubmed.ncbi.nlm.nih.gov/33156746

Cost-utility analysis of the fixed-dose combination of dolutegravir/abacavir/lamivudine as initial treatment of HIV+ patients in Spain

Autor: Moreno Guillén, Santiago, Losa García, Juan Emilio, Berenguer Berenguer, Juan, Martínez Sesmero, José Manuel, Cenoz Gomis, Santiago, Graefehain, Ruth, Sánchez-Cambronero, David López, Parrondo García, Francisco Javier

Publikováno v: Farmacia Hospitalaria, Volume: 41, Issue: 5, Pages: 601-610, Published: OCT 2017

Objective: Fixed-dose combinations of antiretroviral drugs have meant an important step forward in simplifying treatment and improving com-pliance and has led to an increased effectiveness of therapy, a viral load decrease and improving the quality o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______624::b182c3d3da28d978ac0aae33a6d05bbd
http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S1130-63432017000500601&lng=en&tlng=en